Compare GDRX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | NTLA |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.1M | 986.9M |
| IPO Year | 2020 | 2016 |
| Metric | GDRX | NTLA |
|---|---|---|
| Price | $2.76 | $9.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | $5.25 | ★ $19.83 |
| AVG Volume (30 Days) | 1.8M | ★ 4.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $800,651,000.00 | $57,528,000.00 |
| Revenue This Year | $2.30 | $1.96 |
| Revenue Next Year | $2.91 | N/A |
| P/E Ratio | $32.60 | ★ N/A |
| Revenue Growth | 1.30 | ★ 33.52 |
| 52 Week Low | $2.61 | $5.90 |
| 52 Week High | $5.81 | $28.25 |
| Indicator | GDRX | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 40.92 |
| Support Level | $2.62 | $9.15 |
| Resistance Level | $2.97 | $9.68 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | 0.05 | 0.40 |
| Stochastic Oscillator | 39.44 | 56.03 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.